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Background: Blood coagulation is an essential determinant of coronary artery disease (CAD). Soluble Endothelial
Protein C Receptor (sEPCR) may be a biomarker of a hypercoagulable state. We prospectively investigated the
relationship between plasma sEPCR levels and the risk of cardiovascular events (CVE).
Methods: We measured baseline sEPCR levels in 1673 individuals with CAD (521 with acute coronary syndrome
[ACS] and 1152 with stable angina pectoris [SAP]) from the AtheroGene cohort. During a median follow up of 3.7
years, 136 individuals had a CVE. In addition, 891 of these CAD patients were genotyped for the PROCR rs867186
(Ser219Gly) variant.
Results: At baseline, sEPCR levels were similar in individuals with ACS and SAP (median: 111 vs. 115 ng/mL
respectively; p=0.20). Increased sEPCR levels were found to be associated with several cardiovascular risk factors
including gender (p=0.006), soluble Tissue Factor levels (p=0.0001), diabetes (p=0.0005), and factors reflecting impaired
renal function such as creatinine and cystatin C (p<0.0001). sEPCR levels were not significantly associated with the risk
of CVE (median: 110 and 114 ng/mL in individuals with and without future CVE respectively; p=0.68). The rs867186
variant was found to explain 59% of sEPCR levels variability (p<10-200) but did not associate with CVE risk.
Conclusion: Our findings show that in patients with CAD, circulating sEPCR levels are related to classical cardiovascular
risk factors and renal impairment but are not related to long-term incidence of CVE.
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Coronary artery disease (CAD) is the leading cause of
death in the developed world [1]. It is an inflammatory
process that involves cellular and molecular responses to
endothelial dysfunction [2]. One such response is blood
coagulation, and recent studies demonstrate that blood
coagulation is an essential determinant of the risk of
CAD complications [2,3].* Correspondence: pmorange@ap-hm.fr
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reproduction in any medium, provided the orThe protein C (PC) anticoagulant pathway plays a
pivotal role in controlling thrombosis and in limiting the
inflammatory response. It may also reduce endothelial
cell apoptosis in response to inflammatory cytokines and
ischemia [3,4]. The endothelial PC receptor (EPCR) is
important to these processes. Mainly expressed on the
endothelial cells of large vessels [5-7], by binding to PC,
EPCR accelerates the rate of PC activation approxi-
mately twenty fold in vivo [8]. Once PC is activated
(Activated PC, APC), EPCR also mediates its anti-
apoptotic effect on endothelial cells [9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kallel et al. BMC Medical Genetics 2012, 13:103 Page 2 of 8
http://www.biomedcentral.com/1471-2350/13/103In addition to endothelial cell-bound EPCR, a soluble
form of EPCR (sEPCR) circulates in human plasma result-
ing from EPCR membrane shedding mediated by a metal-
loprotease [7,10], probably TACE/ADAM17 [11]. This
process occurs constitutively and is amplified by thrombin
and some inflammatory cytokines (e.g., TNFα, IL-1β)
[4,11]. sEPCR binds PC and APC with the same affinity as
the original membrane form of EPCR and may inhibit
both PC activation and APC anticoagulant activity [12]. In
addition, sEPCR modulates inflammation by binding to
activated neutrophils [13,14] and also reportedly binds to
factor VIIa, reducing the ability of FVIIa to activate FX
[15]. Moreover, high levels of plasma sEPCR were
observed in patients with clinical conditions in which
thrombin is generated, such as CAD [13,16], and
decreased sEPCR levels were observed in another study of
patients on anticoagulant therapy [14].
These data all suggest that sEPCR may act as a pro-
coagulant by reducing antithrombotic and anti inflam-
matory effects. However, data regarding the association
between sEPCR plasma levels and the risk of throm-
bosis are sparse and contradictory. Uitte de Willige
et al.[17], reported that a high level of sEPCR increased
the risk of venous thrombosis, whereas another retro-
spective case/control study showed that patients with
increased sEPCR levels had a reduced risk of myocardial
infarction (MI) [18].
Several studies demonstrated that sEPCR levels were
strongly genetically controlled [17-22]. The rs867186
diallelic single nucleotide polymorphism in the PROCR
gene (g.6936A_G, c.4600A_G), resulting in a serine-to
glycine substitution at codon 219 in the membrane-
spanning domain of EPCR, explains between 56% and
87% of the variations in sEPCR levels [17,20,23]. The G
allele tags the A3 haplotype (4 common PROCR haplo-
types have been identified in whites) and is associated
with increased shedding of EPCR from the endothelial
membrane, both by rendering the receptor more sensi-
tive to cleavage [24] and by leading to a truncated
mRNA through alternative splicing [25]. Besides this
important genetic effect, little is known about the asso-
ciation between sEPCR plasma levels and other environ-
mental cardiovascular risk factors.
Since markers of procoagulable state are of major rele-
vance to CAD, sEPCR could be a risk factor or a predictor
of cardiovascular events (CVE) in individuals with CAD.
We tested this hypothesis in the AtheroGene prospective
cohort. We also studied the relation between sEPCR levels
and conventional cardiovascular risk factors.
Methods
Study population
The Athero Gene study is a prospective cohort of CAD
patients enrolled during several successive phases ofrecruitment between November 1996 and February
2004 [26]. Briefly, patients who underwent coronary
angiography at the Medical Department of the Johannes
Gutenberg-University Mainz or the Bundeswehrzen-
tralkrankenhaus Koblenz and who had at least one sten-
osis >30% diagnosed in a major coronary artery were
enrolled in the cohort. Unstable angina was classified by
Braunwald classification (class B or C). Follow-up infor-
mation was obtained on non-fatal myocardial infarction
(MI) and on death from cardiovascular (CV) causes
(fatal MI, heart failure as a consequence of MI, ven-
tricular arrhythmia, fatal stroke and other cause of vas-
cular deaths). Information on the cause of death was
obtained from the hospital or from the patient’s general
practitioner.
Among patients recruited in the early phase of the
study, insufficient plasma remained for sEPCR testing.
Therefore, this study included only patients recruited
after June 1999 (n = 1673 - second round of the Athero-
Gene Study). Among these, 525 (31%) presented an
acute coronary syndrome (ACS) at entry (314 unstable
angina and 211 acute MI). The remaining individuals
presented a stable angina pectoris (SAP) at entry. All
individuals were followed up for a median time of 3.7
years (maximum 6.2) and 136 experienced a CVE (71
non-fatal MI and 65 CV deaths).
Study participants had German nationality, were inhabi-
tants of the Rhein-Main area, and were of European des-
cent. The study was approved by the ethics committee of
the University of Mainz. Participation was voluntary, and
each participant gave written informed consent.Laboratory methods
Blood was drawn from all study subjects under stan-
dardized conditions before coronary angiography was
performed. Samples were stored at −80°C until ana-
lysis. Plasma sEPCR levels were measured by enzyme
linked ImmunoSorbent Assay (ELISA) according to the
manufacturer’s instructions. The asserachrom sEPCR
ELISA kits were from Diagnostica Stago (Asnière,
France) and the inter-assay variability was 7.5%. Other
biological parameters were measured as previously
described [27].Genotype analysis
DNA was available in a subsample of 891 CAD patients
among which 77 experienced a CVE during the follow-
up. In these patients, five PROCR single nucleotide poly-
morphisms (SNPs), including the PROCR rs867186
(Ser219Gly), were typed using the Affymetrix Genome-
Wide Human SNP 6.0 array as part of a previously
described genome-wide association study [28].
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Associations between baseline cardiovascular risk factors
and CVE were tested by ANOVA and Chi2 analyses.
Associations between sEPCR levels, haemostatic para-
meters and other cardiovascular risk factors were investi-
gated through Pearson correlation coefficients adjusted
for age and sex. sEPCR was log transformed to remove
positive skewness. The relationship between sEPCR (con-
sidered as continuous variables or interquartiles) and
CVE was tested by Cox regression analysis. Two models
were successively fitted: model 1was first adjusted for age
and sex; model 2 was additionally adjusted for clinical
status (ACS vs. stable angina), smoking status, body mass
index, diabetes, hypertension, HDL-cholesterol, triglycer-
ide, CRP, number of stenosed vessels, and medication use
(heparin, beta-blockers, ACE-inhibitors, calcium antago-
nists and statins).
Association of PROCR SNPs with CVE was tested by
the Cochran-Armitage trend test [29] and by a Cox re-
gression analysis, while their association with log sEPCR
levels was tested by a linear model. Linkage disequilib-
rium and haplotype analyses of PROCR SNPs were con-
ducted using the THESIAS software [30].
All analyses were performed with SAS software, version
9.1 (SAS Institute Inc., Cary,NC, USA). P-values< 0.05
were considered statistically significant.Results
Baseline characteristics of individuals according to
cardiovascular outcome
Table 1 shows the baseline characteristics of the CAD
patients according to outcome. In the group with occur-
rence of CVE during follow-up, there was a higher pro-
portion of females, patients presented more often with an
ACS and with a history of previous MI, and a higher
prevalence of diabetes was observed. The number of sten-
osed coronary arteries was also higher in this group. There
was a marked increase in CRP, TAFIa/TAFIai and TFPI
levels, and a slight elevation in D-dimer levels. Factors
reflecting deteriorationof renal function such as creatinin
and cystatin C were also markedly increased.Association between sEPCR levels and cardiovascular risk
factors
sEPCR levels were similar in patients with ACS at base-
line compared to those with SAP at baseline (p=0.20;
Table 2). The highest correlations between sEPCR and
other biological measurements were observed for creati-
nin (r = 0.14) and cystatin C (r = 0.17) (Table 2). Other
significant correlations were found with soluble tissue
factor (sTF) (r = 0.11) and total amount of TAFI (t-TAFI)
(r = 0.08). Plasma sEPCR levels were higher in males and
in diabetic patients, but were decreased in smokers.Association between sEPCR levels and cardiovascular
outcome
sEPCR levels were not significantly different between
individuals with or without future CVE, regardless of
whether sEPCR was studied as continuous variable or in
quartiles (Table 3). Likewise, there was no significant as-
sociation when individuals with ACS at baseline were
studied separately from those with SAP at baseline (data
not shown).
PROCR SNPs analysis
In the subsample of CAD patients with DNA available,
five PROCR SNPs were genotyped: rs6088738,
rs6088747, rs2069940, rs867186 and rs1415774. These
SNPs were in strong linkage disequilibrium, with
rs6088747 and rs867186 being in complete association
(pairwise r2~1) with rs1415774 and rs2069940, respect-
ively (Table 4). None of these SNPs were associated with
the risk of future CVE (Table 5). In particular, the allele
frequency of the rs867186-G allele was 0.11 both in
patients with and without future CVE (Table 5). As
expected, the rs867186 variant was strongly associated
with sEPCR levels and explained 59.1% (p < 10-200) of
their variability. The rs867186-G allele was associated
with increased sEPCR levels in a fairly additive fashion,
the observed log sEPCR levels being 4.66±0.29, 5.48±0.26
and 5.90±0.37 in AA (n = 708), AG (n = 172) and GG
(n = 11) carriers. This association was homogeneous in
patients with or without future CVE, in men and in
women, and was not modified after adjusting for the
studied cardiovascular risk factors (data not shown).
Further haplotype analysis revealed that the rs867186-G
allele was carried out by a single haplotype, that was the
only one associated with sEPCR levels (Table 6).
Of note, in this sample, the Hazard Ratio (HR) for fu-
ture CVE associated with an increase of log-sEPCR (on
continuous scale) was 0.84 [0.35 - 2.02] (p = 0.69) in car-
riers of the rs867186 AA genotype while an opposite
trend (HR of 4.88 [0.87 - 27.4] (p = 0.07) was observed
in carriers of the rs867186-G allele. The test for homo-
geneity of these two HRs was borderline (p = 0.075).
Discussion
To the best of our knowledge, this is the first prospect-
ive study that investigates the association between
sEPCR levels and CAD. Contrary to our initial hypoth-
esis, there was no association between sEPCR levels and
future CVE. Moreover both individuals with ACS and
SAP at baseline had similar sEPCR levels.
Only one previously published case–control study
examined the relationship between sEPCR levels and
CAD [18]. In this work, stratification of sEPCR in quar-
tiles according to the levels in controls showed that,
compared to the first quartile, the OR for subjects with
Table 1 Baseline characteristics of coronary artery disease (CAD) patients according to the outcome during follow-up
Characteristics No cardiovascular event n=1537 Cardiovascular event n=136 Association Test
Age, years 61.2 ± 9.5 62.8 ± 10.5 p = 0.059
Females 323 (21 %) 39 (29%) p = 0.050
Acute coronary syndrome 467 (30 %) 58 (43 %) p = 3.78 10-3
Previous myocardial infarction 586 (38 %) 65 (48 %) p = 0.028
Number of stenosed coronary arteries
one vessel 438 (29 %) 21 (15 %)
two vessels 479 (31 %) 43 (32 %) p = 1.31 10-3
three vessels 620 (40 %) 72 (53 %)
Body mass index (kg/m2) 27.7 ± 3.9 27.8 ± 3.8 p = 0.927
Current smoker 304 (20 %) 33 (24 %) p = 0.219
Diabetes mellitus 240 (16 %) 43 (32 %) p = 1.17 10-5
Hypertension 1151 (75 %) 105 (77 %) p = 0.606
Medications at enrollment
Heparin 521 (34 %) 55 (40 %) p = 0.132
Antiplatelet therapy 1327 (86 %) 108 (79 %) p = 0.039
Statins 800 (52 %) 68 (50 %) p = 0.277
Beta-blocker 1026 (67 %) 80 (59 %) p = 0.072
ACE-inhibitor 770 (50 %) 84 (62 %) p = 9.41 10-3
Calcium antagonists 197 (13 %) 25 (18 %) p = 0.085
Total cholesterol (mgdL-1) 197 ± 45 205 ± 51 p = 0.038
HDL-cholesterol (mgdL-1) 49.4 ± 13.5 48.1 ± 13.6 p = 0.290
Triglyceride (mgdL-1) 129 (95–182) 130 (100–183) p = 0.143
CRP (mgL-1) 2.39 (1.02 - 6.14) 4.59 (1.89 - 11.7) p = 8.41 10-6
Fibrin monomers (μmL) 3.90 (2.64 - 5.33) 3.32 (2.64 - 5.34) p = 0.514
D-dimers (μgmL-1) 0.34 (0.24 - 0.52) 0.39 (0.25 - 0.78) p = 0.024
t-TAFI (μg mL-1) 12.0 ± 2.7 12.4 ± 2.7 p = 0.196
TAFIa/TAFIai (ngmL-1) 10.48 (8.13 - 13.95) 11.59 (9.00 - 15.08) p = 2.75 10-3
Soluble Tissue factor (pgmL-1) 158 (124–204) 159 (124–208) p = 0.641
f-TFPI (ngmL-1) 10.80 (7.61 - 18.89) 13.46 (9.34 - 25.89) p = 7.54 10-3
Creatinine (mgdL-1) 0.96 ± 1.03 1.03 ± 0.29 p = 5.59 10-4
Cystatin C (mgL-1) 0.81 (0.71 - 0.94) 0.86 (0.72 - 1.08) p = 1.28 10-4
sEPCR(ngmL-1) 114 (93–161) 110 (91–177) p = 0.654
t-TAFI measures total Thrombin Activating Fibrinolysis Inhibitor in plasma ; TAFIa/TAFIai measures activated TAFI levels in plasma; f-TFPI = free form of tissue
factor pathway inhibitor 1.
Categorical variables are presented as n (%), and continuous variables as mean ± SD or median (25th - 75th percentile) for skewed variables (for these variables,
tests were performed on log-transformed distribution).
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result differs from ours, as we did not find a protective
effect of high sEPCR levels in our cohort. Among the
possible explanations for this discrepancy are differences
in study design (retrospective versus prospective) and in
the age of study participants at baseline (median age of
42 years in the case–control study versus 62 years in our
prospective study). It could also be argued that the low
number of events observed during the follow-up with
median time of 3.7 years may have limited our power to
detect any association of sEPCR with future CVE, espe-
cially if sECPR effects, if any, exert at a later time period.Nevertheless, our study was large enough to detect the
association of several biomarkers, including parameters
characterizing the renal function, with the risk of future
CVE.
The physiological role of sEPCR is still unclear. Ele-
vated plasma sEPCR levels may increase thrombotic risk
by inhibiting PC and APC and by competing with mem-
brane associated EPCR for PC binding [12]. High plasma
sEPCR levels might also result in low residual EPCR
levels on the membrane, resulting in reduced PC activa-
tion. Alternatively, higher levels of endothelial or soluble
EPCR may shift the haemostatic balance toward
Table 2 Association between sEPCR, haemostatic
parameters and other cardiovascular risk factors,






Body mass index 0.05 p=0.06
Total cholesterol −0.02 p=0.40
HDL cholesterol −0.02 p=0.31
Triglyceride 0.05 p=0.04
CRP −0.06 p=0.01




Soluble Tissue factor 0.11 p<0.0001
f-TFPI −0.02 p=0.38
Creatinine 0.14 p<0.0001






Female 107 (89–155) p=0.006
Acute coronary syndrome
No 115 (94–166)
Yes 111 (90–156) p=0.20
Current smoking
No 115 (94–170)
Yes 108 (88–148) p=0.005
Diabetes
No 111 (91–158)
Yes 123 (101–182) p=0.0005
Hypertension
No 111 (91–147)
Yes 115 (94–168) p=0.12
* Tests performed on correlations (1) or means (2) adjusted on age and sex;
skewed variables were log-transformed.
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by the FVIIa-tissue factor (TF) complex. Low sEPCR
levels, on the other hand, also might reflect increased
thrombotic risk. This could be caused by low EPCR ex-
pression on the endothelium or by membrane-bound
EPCR that is resistant to ADAM17 shedding [24], result-
ing in decreased APC formation. Further studies are
needed to investigate the relationship between EPCR
membrane expression and its circulating form. Indeed, a
recent study reported that TNFα causes a rapid down-
regulation of membrane associated EPCR expressionwithout markedly affecting the spontaneous release of
sEPCR by arterial endothelial cells [31].
With respect to parameters affecting sEPCR levels, we
confirmed in a subsample of 891 patients who had both
sEPCR measured and DNA available the major impact of
the Ser219Gly EPCR polymorphism on sEPCR levels
[17-22]. However, we did not observe any evidence in
favour of an association of Ser219Gly with future CVE.
This is unlikely due to a loss power since the same allele
frequencies were observed in both groups of patients with
or without future CVE. Conversely, this is in line with a
recent review demonstrating that this polymorphism is
unlikely a risk variant for arterial thrombosis but more
likely a risk variant for venous thrombosis [32]. Neverthe-
less, it would be highly interesting to investigate whether
the trend of association observed between sEPCR and
CVE risk in rs867186-G carriers only could replicate in a
much larger cohort with a longer follow-up.
In addition, we have explored the association of plasma
sEPCR levels with haemostatic variables. sEPCR levels cor-
related with sTF and t-TAFI levels. Previous studies
demonstrated that sTF levels, but not t-TAFI, were pre-
dictive of cardiovascular death in individuals with CAD
[27,33]. In atherosclerosis, circulating sTF can arise not
only by membrane shedding but also by alternative spli-
cing [34]. Several recent observations indicate that FVIIa
interacts with EPCR in vivo [35]. Moreover, analysis of
FVII, FVIIa, and sEPCR levels in a large group of healthy
individuals revealed that those with higher sEPCR levels
also had higher levels of circulating FVII and FVIIa [19].
The association observed between sEPCR and sTF in the
present study underlines the interplay between EPCR and
the extrinsic coagulation pathway.
Several papers [14,36] have previously suggested that
sEPCR levels could be a reliable marker of thrombin
generation. Our study did not favour this hypothesis as
no relation was observed between sEPCR levels and
markers of thrombin generation such as D-dimer, fibrin
monomers, and TAFIa/TAFIai levels.
We also evaluated the relationship between sEPCR
levels and traditional cardiovascular risk factors. We
confirmed recent data [31] demonstrating that gender
strongly correlates with sEPCR levels, with higher circu-
lating sEPCR levels observed in males. We found a
strong association between diabetes and sEPCR levels.
These results are in line with those from Ireland et al.
[23] who observed a contribution of duration of diabetes
on sEPCR levels in the Ealing Diabetes Study of Coagu-
lation (EDSC). Interestingly, we also found a strong cor-
relation between sEPCR and parameters reflecting
kidney functions such as creatinine and cystatin C. High
sEPCR levels were reported in hemodialysis patients and
significantly decreased after kidney transplantation [37].
This finding extends those already reported on the
Table 5 Genotype distribution of the PROCR
polymorphisms in CAD patients according to the
outcome during follow-up
No cardiovascular
event N = 805
Cardiovascular
events N = 77
rs6088738
GG 469 (59%) 46 (60%)
GA 291 (36%) 28 (36%)
AA 40 (5%) 3 (4%)
MAF(1) 0.232 0.221
P(2) p = 0.752
rs6088747
TT 280 (35%) 18 (24%)
TG 380 (47%) 43 (56%)
GG 145 (18%) 16 (20%
MAF 0.416 0.487
P p = 0.092
rs867186
AA 639 (79%) 62 (80%)
AG 157 (20%) 13 (17%)
GG 9 (1%) 2 (3%)
MAF 0.109 0.110
P p = 0.948
(1) MAF: Minor Allele Frequency.
(2) P-value of the Cochran-Armitage trend.
As rs2069940 and rs1415774 were in complete association with rs867186 and
rs6088747, respectively, their genotype distributions were not displayed.
Table 3 Hazard ratios (95% confidence interval) for cardiovascular death or myocardial infarction according to
quartiles of baseline sEPCR levels
Q1 Q2 Q3 Q4 p (continuous scale)
Quartiles ranges 48 - 93 94 - 113 114 - 162 163 - 600
Patients with events/ all patients 36/418 35/418 29/419 36/418
Model 1 reference 1.00 (0.63 - 1.60) 0.85 (0.52 - 1.39) 1.03 (0.65 - 1.64) p=0.57
p=0.99 p=0.51 p=0.89
Model 2 reference 1.11 (0.67 - 1.83) 0.96 (0.57 - 1.62) 1.13 (0.69 - 1.87) p=0.38
p=0.69 p=0.87 p=0.63
Model 1: adjusted on age and sex; model 2: adjusted on age, sex, acute coronary syndrome, smoking status, body mass index, diabetes, hypertension,
HDL-cholesterol, triglyceride, CRP, number of stenosed vessels, and medication use (heparin, beta-blockers, ACE-inhibitors, calcium antagonists and statins).
P-value was calculated on continuous log-transformed sEPCR.
Table 4 Pairwise linkage disequilibrium observed at the PROCR locus in the AtheroGene study (n = 891)
rs6088738 rs6088747 rs2069940 rs867186 rs1415774
rs6088738 - −0.97 −0.93 −0.93 −1
rs6088747 0.21 - −0.98 −0.98 0.99
rs2069940 0.03 0.09 - 1 −1
rs867186 0.03 0.09 1 - −1
rs1415774 0.21 0.97 0.09 0.09 1
Pairwise linkage disequilibium was expressed in terms of D' (upper-right triangle) and r2 (bottom-left triangle) values.
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function [38].
Conclusion
In conclusion, we reported the first prospective study inves-
tigating the association of sEPCR with CAD. We observed
no association between sEPCR levels and acute coronary
syndrome or with future cardiovascular events. However,
sEPCR levels were associated with conventional cardiovas-
cular risk factors such as diabetes and parameters reflecting
kidney function. More research is warranted to elucidate
the pathogenic effect of sEPCR in CAD.
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